These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37269671)

  • 1. Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation.
    Ibrahim TM; Abada G; Dammann M; Maklad RM; Eldehna WM; Salem R; Abdelaziz MM; El-Domany RA; Bekhit AA; Beockler FM
    Eur J Med Chem; 2023 Sep; 257():115534. PubMed ID: 37269671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pyrazolylpyrazoline derivatives as dual acting antimalarial-antileishamanial agents: synthesis, biological evaluation and molecular modelling simulations.
    Bekhit AA; Lodebo ET; Hymete A; Ragab HM; Bekhit SA; Amagase K; Batubara A; Abourehab MAS; Bekhit AEA; Ibrahim TM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2320-2333. PubMed ID: 36036155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies.
    Sabt A; Eldehna WM; Ibrahim TM; Bekhit AA; Batran RZ
    Eur J Med Chem; 2023 Jan; 246():114959. PubMed ID: 36493614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, in vitro biological evaluation and in silico studies of certain arylnicotinic acids conjugated with aryl (thio)semicarbazides as a novel class of anti-leishmanial agents.
    Eldehna WM; Almahli H; Ibrahim TM; Fares M; Al-Warhi T; Boeckler FM; Bekhit AA; Abdel-Aziz HA
    Eur J Med Chem; 2019 Oct; 179():335-346. PubMed ID: 31260888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spiro heterocycles bearing piperidine moiety as potential scaffold for antileishmanial activity: synthesis, biological evaluation, and
    Mohamed MAA; Kadry AM; Bekhit SA; Abourehab MAS; Amagase K; Ibrahim TM; El-Saghier AMM; Bekhit AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):330-342. PubMed ID: 36444862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents.
    Bekhit AA; Hassan AM; Abd El Razik HA; El-Miligy MM; El-Agroudy EJ; Bekhit Ael-D
    Eur J Med Chem; 2015 Apr; 94():30-44. PubMed ID: 25768697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation, Structure - Activity relationship studies of quinoline-imidazole derivatives as potent antimalarial agents.
    Roy D; Anas M; Manhas A; Saha S; Kumar N; Panda G
    Bioorg Chem; 2022 Apr; 121():105671. PubMed ID: 35168120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplasmodial and Antileishmanial Activities of a New Limonoid and Other Constituents from the Stem Bark of
    Amang À Ngnoung GA; Nganso Ditchou YO; Leutcha PB; Dize D; Tatsimo SJN; Tchokouaha LRY; Kowa TK; Tembeni B; Mamoudou H; Poka M; Demana PH; Siwe Noundou X; Fekam Boyom F; Meli Lannang A
    Molecules; 2023 Oct; 28(20):. PubMed ID: 37894704
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
    Bekhit AA; Saudi MN; Hassan AMM; Fahmy SM; Ibrahim TM; Ghareeb D; El-Seidy AM; Nasralla SN; Bekhit AEA
    Eur J Med Chem; 2019 Feb; 163():353-366. PubMed ID: 30530172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
    Karad SC; Purohit VB; Thakor P; Thakkar VR; Raval DK
    Eur J Med Chem; 2016 Apr; 112():270-279. PubMed ID: 26900659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, molecular modeling and biological screening of some pyrazole derivatives as antileishmanial agents.
    Bekhit AA; Saudi MN; Hassan AM; Fahmy SM; Ibrahim TM; Ghareeb D; El-Seidy AM; Al-Qallaf SM; Habib HJ; Bekhit AEA
    Future Med Chem; 2018 Oct; 10(19):2325-2344. PubMed ID: 30215271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Antiplasmodial Potential of C2 and C8 Modified Quinolines: in vitro and in silico Study.
    Kumar R; Sharma R; Kumar I; Upadhyay P; Dhiman AK; Kumar R; Kumar R; Purohit R; Sahal D; Sharma U
    Med Chem; 2019; 15(7):790-800. PubMed ID: 30324888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, antileishmanial, antimalarial evaluation and molecular docking study of some hydrazine-coupled pyrazole derivatives.
    Berhe HG; Birhan YS; Beshay BY; Habib HJ; Hymete A; Bekhit AA
    BMC Chem; 2024 Jan; 18(1):9. PubMed ID: 38191485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and development of novel N-(4-aminobenzoyl)- l-glutamic acid conjugated 1,3,5-triazine derivatives as Pf-DHFR inhibitor: An in-silico and in-vitro study.
    Adhikari N; Choudhury AAK; Shakya A; Ghosh SK; Patgiri SJ; Singh UP; Bhat HR
    J Biochem Mol Toxicol; 2023 Apr; 37(4):e23290. PubMed ID: 36541419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
    Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
    Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinoline Derivatives as Promising Scaffolds for Antitubercular Activity: A Comprehensive Review.
    Owais M; Kumar A; Hasan SM; Singh K; Azad I; Hussain A; Suvaiv ; Akil M
    Mini Rev Med Chem; 2024; 24(13):1238-1251. PubMed ID: 38185891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and in vitro biological evaluation of novel thiazolopyrimidine derivatives as antileishmanial compounds.
    Istanbullu H; Bayraktar G; Akbaba H; Cavus I; Coban G; Debelec Butuner B; Kilimcioglu AA; Ozbilgin A; Alptuzun V; Erciyas E
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e1900325. PubMed ID: 32484266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of dehydroxy isoquine and isotebuquine as promising antileishmanial agents.
    Romero AH; Rodríguez N; López SE; Oviedo H
    Arch Pharm (Weinheim); 2019 May; 352(5):e1800281. PubMed ID: 30994941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, antimalarial, antileishmanial evaluation, and molecular docking study of some 3-aryl-2-styryl substituted-4(3H)-quinazolinone derivatives.
    Seifu GW; Birhan YS; Beshay BY; Hymete A; Bekhit AA
    BMC Chem; 2022 Dec; 16(1):107. PubMed ID: 36461074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.